

Rolf Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2658146/publications.pdf>

Version: 2024-02-01

8
papers

417
citations

1478505
6
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

718
citing authors

#	ARTICLE	IF	CITATIONS
1	HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments. Topics in Medicinal Chemistry, 2019, , 133-156.	0.8	1
2	Highlights of the Structure–Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). Journal of Medicinal Chemistry, 2018, 61, 4052-4066.	6.4	42
3	Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stillbene Analog with Good Oral Bioavailability. Journal of Medicinal Chemistry, 2018, 61, 1153-1163.	6.4	17
4	<i>In Vitro</i> Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	117
5	Discovery of fluorobenzimidazole HCV NS5A inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5462-5467.	2.2	5
6	<i>In Vitro</i> Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor. Antimicrobial Agents and Chemotherapy, 2015, 59, 1505-1511.	3.2	109
7	Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. Journal of Medicinal Chemistry, 2014, 57, 2047-2057.	6.4	120
8	High potency improvements to weak aryl uracil HCV polymerase inhibitor leads. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4367-4369.	2.2	6